The spread of drug-resistant pathogens, known as antimicrobial resistance (AMR), is a growing public health concern. Overuse of antibiotics, or not using them as prescribed, contributes to growth of resistant bacteria, which renders antibiotics less effective or ineffective. It is estimated that by 2050, AMR infections could cause 10 million deaths annually.9 Johnson & Johnson has a longstanding commitment to develop and responsibly deploy innovative technologies and treatments to combat the growing threat of AMR on multiple fronts.
In 2019, we joined the U.S. Centers for Disease Control and Prevention’s AMR Challenge to combat antimicrobial resistance by submitting an actionable commitment for change. The AMR Challenge is a way for governments, private companies, and non-governmental organizations worldwide to make formal commitments that further the progress against antimicrobial resistance. Read our commitment on the AMR Challenge page.
Our performance was recognized in four core categories: Research & Development (R&D), Responsible Manufacturing, Appropriate Access, and Stewardship. Johnson & Johnson is making the second-largest R&D investment in relevant disease areas as identified by the Benchmark and is stewarding one of the largest antimicrobial pipelines to ensure antimicrobials remain a backbone of modern medicine.
These efforts are clearly exemplified in our work to tackle drug-resistant TB (DR-TB). DR-TB is responsible for one-third of all AMR-related deaths and is the world’s only airborne drug-resistant infection. Currently, a third of all people with DRTB— approximately 300,000 individuals—are not aware they are infected, posing a major threat to public health and global health security. See our section on Eradicating Tuberculosis.